SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001072613-20-000099
Filing Date
2020-02-13
Accepted
2020-02-13 16:52:28
Documents
1
Group Members
ARCH VENTURE PARTNERS VIII, L.P.ARCH VENTURE PARTNERS VIII, LLCCLINTON BYBEEKEITH CRANDELLROBERT NELSEN

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND VIII, L.P. - DENALI THERAPEUTICS INC. -- SCHEDULE 13G/A(#1) archviii-denali_13g18372.htm SC 13G/A 239489
  Complete submission text file 0001072613-20-000099.txt   241182
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 776-380-6600
ARCH Venture Fund VIII, L.P. (Filed by) CIK: 0001605598 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90223 | Film No.: 20611592
SIC: 2836 Biological Products, (No Diagnostic Substances)